IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Pentoxifylline for Primary Biliary Cirrhosis
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Primary biliary cirrhosis (PBC) is cholestatic liver disease characterized by progressive destruction of small bile ducts within the liver that can lead to end stage liver disease and all its complications.
Although ursodeoxycholic acid (UDCA) is associated with increased survival in many patients with PBC, there is absence of an adequate response to UDCA in a significant proportion of PBC patients.
Tumor necrosis factor alpha (TNF-alpha) is a cytokine that plays an important role in the pathogenesis of PBC. Other fibrosis biomarkers such as tissue metallo proteinase 1 (TIMP-1) are associated with progression of liver fibrosis in PBC. Pentoxifylline (PTX) is a methylxanthine derivative that inhibits pro-inflammatory cytokines and also has shown anti-fibrotic effects in serum of patients with PBC. Furthermore, PTX has well known clinical and safety profiles. The main hypothesis of this study is that therapy with pentoxifylline (PTX) will result in improvement of liver disease in PBC patients who are incomplete responders to UDCA.
The focus of this proposal is on the effectiveness of PTX in improving laboratory parameters of liver disease and levels of cytokines involved in the pathogenesis of the disease in patients with PBC.
| Condition | Intervention | Phase |
|---|---|---|
| Primary Biliary Cirrhosis | Drug: Pentoxifylline | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Pilot Study of Pentoxifylline for the Treatment of Primary Biliary Cirrhosis |
- Change in Serum Alkaline Phosphatase Levels. [ Time Frame: 6 months ]Serum alkaline phosphatase levels at entry and at 6 months of therapy with PTX will be measured and compared.
- Change in Serum Concentration of Tissue Inhibitor Metalloproteinase 1 (TIMP-1) After PTX Therapy. [ Time Frame: 6 months ]Serum concentration of tissue inhibitor metalloproteinase 1 (TIMP-1), a fibrosis biomarker of interest, will be measured and the change in serum levels between entry and end of study will be calculated.
- Safety of Therapy in the Pilot Study of PTX Therapy in Patients With PBC Will be Assessed [ Time Frame: 6 months ]The number of participants that experienced any severe adverse events will be monitored and recorded.
| Enrollment: | 20 |
| Study Start Date: | November 2010 |
| Study Completion Date: | March 2013 |
| Primary Completion Date: | June 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Pentoxifylline 400 mg TID
This study is an open label pilot with only one arm.
|
Drug: Pentoxifylline
Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
|
Eligibility| Ages Eligible for Study: | 18 Years to 76 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female patients ages 18 to 76 years.
-
Established diagnosis of PBC based on at least three of the following criteria:
- Detectable anti-mitochondrial antibodies (AMA)
- Cholestatic biochemical pattern
- Liver biopsy compatible with PBC
- Appropriate exclusion of other liver diseases.
- Therapy with UDCA at adequate dose (13-15mg/kg/d) for at least six months and evidence of suboptimal response defined by alkaline phosphatase levels that did not normalize and remain elevated by at least 1.5 times the upper limit of normal.
- No history or present hepatic decompensation (e.g. variceal hemorrhage, encephalopathy, or poorly controlled ascites).
Exclusion Criteria:
- Findings highly suggestive of liver disease of other etiology.
- A score >=10 points on the Revised Scoring System for autoimmune hepatitis (AIH), supporting a diagnosis of PBC/AIH overlap.
- Patients on steroids (systemic), immunosuppressants, or immunomodulatory agents within the previous 6 months.
- Patients with clinical or laboratory evidence suggestive of decompensated cirrhosis.
- Hypersensitivity to PTX or the methylxanthines (caffeine, theophylline, theobromine).
- History of cerebral or retinal hemorrhage.
- Other medical comorbidities (such as cardiac, renal, cancer) that would interfere with completion of the study.
- Patients taking Theophylline or Coumadin because of potential drug-drug interactions with PTX. In addition, patients taking low molecular weight heparin preparations.
- Pregnant or nursing women.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01249092
| United States, Ohio | |
| Cleveland Clinic | |
| Cleveland, Ohio, United States, 44195 | |
| Principal Investigator: | Claudia O. Zein, MD, MSc | The Cleveland Clinic |
More Information
| Responsible Party: | Claudia Zein, MD, Staff Physician, Digestive Disease Institute, The Cleveland Clinic |
| ClinicalTrials.gov Identifier: | NCT01249092 History of Changes |
| Other Study ID Numbers: |
07-1003 |
| Study First Received: | November 24, 2010 |
| Results First Received: | July 31, 2013 |
| Last Updated: | October 16, 2013 |
Keywords provided by Claudia Zein, MD, The Cleveland Clinic:
|
biliary cirrhosis |
Additional relevant MeSH terms:
|
Fibrosis Liver Cirrhosis Liver Cirrhosis, Biliary Pathologic Processes Liver Diseases Digestive System Diseases Cholestasis, Intrahepatic Cholestasis Bile Duct Diseases Biliary Tract Diseases Pentoxifylline |
Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Radiation-Protective Agents Protective Agents Physiological Effects of Drugs Vasodilator Agents Free Radical Scavengers Antioxidants |
ClinicalTrials.gov processed this record on June 23, 2017